nilutamide and Day Blindness studies

nilutamide and Day Blindness

nilutamide has been researched along with Day Blindness in 3 studies

Research Excerpts

Excerpt	Relevance	Reference
"According to the National Prostatic Cancer Project (NPCP) criteria, 43 patients were evaluable for response."	2.67	Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. ( Boccardo, F; Decensi, AU; Fioretto, L; Giuliani, L; Guarneri, D; Macaluso, MP; Martorana, G; Mini, E; Periti, P; Santi, L, 1991)
" Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment."	1.27	Ocular toxicity of Anandron in patients treated for prostatic cancer. ( Dupont, A; Harnois, C; Labrie, F; Malenfant, M, 1986)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

1 (33.33)

18.7374

1990's

1 (33.33)

18.2507

2000's

1 (33.33)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Chan, P	1
Odel, JG	1
Boccardo, F	1
Decensi, AU	1
Guarneri, D	1
Martorana, G	1
Fioretto, L	1
Mini, E	1
Macaluso, MP	1
Giuliani, L	1
Santi, L	1
Periti, P	1
Harnois, C	1
Malenfant, M	1
Dupont, A	1
Labrie, F	1

Studies

Chan, P

Odel, JG

Boccardo, F

Decensi, AU

Guarneri, D

Martorana, G

Fioretto, L

Mini, E

Macaluso, MP

Giuliani, L

Santi, L

Periti, P

Harnois, C

Malenfant, M

Dupont, A

Labrie, F

Trials

1 trial available for nilutamide and Day Blindness

Article	Year
Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer detection and prevention, 1991, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolid	1991

Article

Year

Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.

Cancer detection and prevention, 1991, Volume: 15, Issue:6

Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Humans; Imidazoles; Imidazolid

1991

Other Studies

2 other studies available for nilutamide and Day Blindness

Article	Year
Delayed dark adaptation caused by nilutamide. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2008, Volume: 28, Issue:2 Topics: Age Factors; Aged, 80 and over; Androgen Antagonists; Carcinoma; Dark Adaptation; Dose-Response Rela	2008
Ocular toxicity of Anandron in patients treated for prostatic cancer. The British journal of ophthalmology, 1986, Volume: 70, Issue:6 Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged;	1986

Article

Year

Delayed dark adaptation caused by nilutamide.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2008, Volume: 28, Issue:2

Topics: Age Factors; Aged, 80 and over; Androgen Antagonists; Carcinoma; Dark Adaptation; Dose-Response Rela

2008

Ocular toxicity of Anandron in patients treated for prostatic cancer.

The British journal of ophthalmology, 1986, Volume: 70, Issue:6

Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged;

1986